BI
JANX icon

BVF Inc’s Janux Therapeutics JANX Stock Holding History

BVF Inc’s Portfolio JANX Stock Details JANX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-441,528
Closed -$18.5M – 56
2024
Q2 		$18.5M Sell
441,528
-2,478,290
-85% -$116M 0.52% 34
2024
Q1 		$110M Sell
2,919,818
-1,660,000
-36% -$36.2M 3.02% 6
2023
Q4 		$49.1M Hold
4,579,818
– – 1.23% 21
2023
Q3 		$46.2M Buy
4,579,818
+472,873
+12% +$5.45M 1.24% 22
2023
Q2 		$48.7M Buy
4,106,945
+2,521,268
+159% +$33.7M 1.36% 21
2023
Q1 		$19.2M Buy
1,585,677
+115,343
+8% +$1.92M 0.7% 37
2022
Q4 		$19.4M Hold
1,470,334
– – 0.82% 38
2022
Q3 		$19.9M Hold
1,470,334
– – 0.82% 39
2022
Q2 		$18M Buy
1,470,334
+327,994
+29% +$3.88M 0.87% 35
2022
Q1 		$16.4M Buy
1,142,340
+125,026
+12% +$2.05M 0.66% 39
2021
Q4 		$20.1M Hold
1,017,314
– – 0.73% 40
2021
Q3 		$22M Sell
1,017,314
-159,367
-14% -$4.59M 0.86% 34
2021
Q2 		$29.4M Buy
+1,176,681
New +$26.2M 1.1% 23

Other funds holding JANX

RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $4.89B AUM 251.12% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

BVF Inc's JANX Position: Q3 2024 in Review

BVF Inc sold out of Janux Therapeutics (JANX) in Q3 2024, closing a stake of 441,528 shares — an estimated $18.5M sold.

BVF Inc first reported a position in JANX in Q2 2021 and held it in 13 quarters. The position peaked at $110M in Q1 2024. 160 funds tracked by Wall St. Rank hold JANX as of Q3 2024.

  • BVF Inc reported no remaining Janux Therapeutics position as of Q3 2024 after selling out during the quarter.
  • BVF Inc sold 441,528 Janux Therapeutics shares in Q3 2024, an estimated $18.5M.
  • BVF Inc first reported a position in Janux Therapeutics in Q2 2021 and held it in 13 quarters.
  • BVF Inc's Janux Therapeutics position peaked at $110M in Q1 2024.
  • 160 funds tracked by Wall St. Rank held Janux Therapeutics as of Q3 2024.

Based on BVF Inc's 13F filing for Q3 2024, filed 14 Nov 2024.